Day: September 22, 2022

Phase 1 clinical trial in patients with renal impairment demonstrates balixafortide to be safe and well tolerated Safety findings support potential to use significantly higher doses of balixafortide than those previously investigated Additional observations indicate potential for stimulating prolonged stem cell mobilization, a potentially key advantage in implementing hematopoietic stem cell transplantationALLSCHWIL, Switzerland, Sept. 22, 2022 (GLOBE NEWSWIRE) — Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced the results of a Phase 1 clinical trial with balixafortide (“BLX”), a potent, specific and highly selective macrocycle inhibitor of CXCR4. This study was undertaken to investigate whether dosing of BLX needs to be adjusted in patients with renal...

Transformation to pure-play Innovative Medicines company nears completionFocusing strategy on five core Therapeutic Areas, key technology platforms, and the USAdvancing eight in-market brands with multi-billion dollar peak sales potential and prioritizing pipeline to focus on high-value NMEsContinuing to deliver growing sales, Core Op Inc, and cash flows with consistent shareholder friendly capital allocationBasel, September 22, 2022 — Novartis executives are meeting investors and industry analysts in Basel today, sharing insights into the updated company strategy at the annual Meet Novartis Management event. The meeting will allow participants to learn more about Novartis journey to unite technology leadership in Research and Development with novel access approaches, helping to alleviate some of society’s greatest disease...

         Global Bioenergies: Successful completion of REWOFUEL project Paris, 22 September 2022 – Global Bioenergies announces the end of the REWOFUEL project, which ran from 1 June 2018 to 30 June 2022. This project brought together several European industries such as Repsol, Sekab and Fibenol, with the objective of demonstrating the conversion of wood residues into sustainable high-performance components for road and aviation fuels, and thus participate to the decarbonization efforts of ground and air transportation. The project was coordinated by Global Bioenergies and received €13.8 million in funding from the European Horizon 2020 research and innovation programme. The project, otherwise known by its full name, “Residual Wood Conversion to High-performance drop-in Biofuels”, was funded under contract n° 792104 through the Innovation...